Head-to-head · WeighScore
Dr. Gillis' Wellness Center vs Wisp
The verdict
Wisp takes it — 75.3/100 to 67/100.
Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Dr. Gillis' Wellness Center | Wisp |
|---|---|---|
| WeighScore | 67/100 | 75.3/100 |
| Grade | C | C |
| Scorecard rank | #177 | #57 |
| Semaglutide | $149/mo (starting dose, compounded) | $225/mo (compounded oral) |
| Tirzepatide | Not disclosed | $99/mo (starting dose, brand-name) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Yes |
Graded #177 · C
Strengths
- Sublingual ODT tablets offered as needle-free alternative
- Broad GLP-1 menu: semaglutide, tirzepatide, and retatrutide
- Transparent pricing: $150 starting dose, plans from $149/mo
- Led by board-certified physician/surgeon with 25+ years experience
- No contracts; flexible weekly, bi-weekly, or monthly cadence
Where it loses points
- Specific dose-tier pricing beyond starting plan not detailed
- Compounded vs brand not explicitly stated for all meds
- Smaller clinic vs national telehealth brands
- State licensing list not published
Graded #57 · C
Strengths
- Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
- LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
- Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary
Where it loses points
- Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
- Pharmacy partners not named
- States served not listed publicly
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.